Nirogacestat (Ogsiveo; PF-03084014; CAS 1185282-01-2): NIOSH HD Category 1 SEVENTY-FIFTH Mechanism Class — FIRST γ-SECRETASE INHIBITOR EVER FDA APPROVED — PSEN1/PSEN2 Aspartyl Protease D257+D385 Catalytic Dyad — Notch S3 Intramembrane Cleavage Blocked → NICD Release Prevented → HES1/HEY1 Suppressed — DECIPHER PFS HR 0.29 Desmoid Tumors — SpringWorks Therapeutics NDA 216901 Nov 27 2023 — 707th AI Adversarial Injection Attack on Pharmaceutical EHS Compliance Infrastructure

Introduction: The Failed Alzheimer's Drug That Became Oncology's First γ-Secretase Inhibitor

Few pharmaceutical stories illustrate the tortuous path from mechanism to medicine as dramatically as the γ-secretase inhibitors (GSIs). For more than two decades, the γ-secretase enzyme complex occupied a central position in Alzheimer's disease (AD) drug discovery — the upstream cleaving enzyme that generates the amyloid-β (Aβ) peptide fragments central to the amyloid cascade hypothesis of AD pathogenesis. Blocking γ-secretase should, in theory, halt Aβ production and prevent the amyloid plaques that accumulate in AD brains. By the mid-2000s, pharmaceutical companies had invested billions of dollars in GSI programs: Eli Lilly's semagacestat (LY450139), Bristol-Myers Squibb's avagacestat (BMS-708163), Pfizer's begacestat and PF-03084014, Roche/Genentech's RG7112, and others moved into clinical development with high expectations.

The failures were catastrophic. Semagacestat's Phase 3 IDENTITY and IDENTITY-2 trials (NCT00594568; NCT00762411) were stopped in 2010 when interim analyses showed that patients receiving semagacestat actually worsened cognitively compared to placebo, in addition to developing increased rates of skin cancer (squamous cell carcinoma) and severe gastrointestinal toxicity. The underlying mechanism was clear in retrospect: γ-secretase doesn't just cleave APP to generate Aβ — it cleaves approximately 100 Type I transmembrane substrates, including the Notch1, 2, 3, and 4 receptors. Pan-Notch inhibition disrupts normal gut epithelial renewal (goblet cell metaplasia, intestinal crypt apoptosis), skin homeostasis (squamous differentiation dysregulation), and neuronal Notch-dependent signaling that is entirely distinct from the AD amyloid hypothesis. Avagacestat, administered at lower doses designed to spare Notch, still failed in Phase 2 AD trials and demonstrated a troubling increase in BACE1-independent APP cleavage to Aβ42 (a paradoxical shift to more toxic amyloid species at certain dose ranges). By 2012, the GSI class was widely considered a graveyard of failed hypotheses in AD.

What the AD researchers didn't fully appreciate was that the toxicity profile they viewed as a catastrophic liability — pan-Notch inhibition — was precisely the therapeutic goal for certain oncology indications. Notch signaling is not merely a background housekeeping pathway; it is a potent driver of proliferation, survival, and lineage determination in multiple cancer types. And in desmoid tumors — rare locally aggressive soft-tissue tumors arising from APC or CTNNB1 mutations in fibroblast precursors — the Notch pathway is constitutively activated downstream of the same β-catenin transcriptional program that defines desmoid tumor biology. Pfizer's internal compound PF-03084014, one of several GSIs that never advanced to full AD clinical development, was licensed to SpringWorks Therapeutics in 2019 as part of a spinout of rare disease and specialty oncology programs. Under the name nirogacestat, PF-03084014 became the drug that finally answered the decades-long question of whether any γ-secretase inhibitor could successfully traverse the FDA regulatory pathway.

NDA 216901 was approved on November 27, 2023 — making nirogacestat the first γ-secretase inhibitor ever approved by any regulatory agency worldwide, the first drug ever approved specifically for desmoid tumors, and the 75th mechanistically distinct drug class in the Glyphward adversarial EHS attack series. And like every NIOSH HD Category 1 agent in this series approved after 1971, nirogacestat appears nowhere in the occupational exposure databases maintained by Cority, VelocityEHS, or EHS Insight — creating the null-return adversarial condition that this series was designed to document.

γ-Secretase Complex: Intramembrane Aspartyl Protease Architecture

γ-Secretase is structurally unique among proteases: it is an aspartyl protease that operates within the hydrophobic interior of the lipid bilayer, cleaving Type I transmembrane substrates at positions within or immediately adjacent to their transmembrane domains. The soluble aspartyl proteases (pepsin, renin, cathepsin D, HIV protease) carry out hydrolytic cleavage in aqueous environments where water molecules are abundant; γ-secretase must accomplish the same water-dependent chemistry in an environment where water is excluded from the lipid bilayer core. This necessitates a specialized active-site architecture where local water molecules are carefully coordinated, and where the two catalytic aspartate residues (D257 and D385 in PSEN1) are oriented to position a nucleophilic water molecule for attack on the scissile peptide bond.

The four obligate subunits of the γ-secretase complex are:

PRESENILIN-1 (PSEN1; gene chromosome 14q24.2; 467 amino acids; 9 predicted transmembrane domains): The catalytic subunit. PSEN1 harbors the aspartyl protease active site in transmembrane domains 6 and 7 — D257 (TMD6) and D385 (TMD7) — forming the catalytic dyad. PSEN1 undergoes obligate endoproteolytic cleavage (autoproteolysis) between residues L292 and A293 in the hydrophilic loop connecting TMD6 and TMD7, generating an N-terminal fragment (NTF; residues 1–292) and a C-terminal fragment (CTF; residues 293–467). The NTF and CTF remain tightly associated as a heterodimer. This autoproteolysis is required for proteolytic activity — it positions D257 (in NTF-TMD6) and D385 (in CTF-TMD7) in catalytic geometry. PSEN2 (gene chromosome 1q42.13; 448 amino acids) is homologous (~67% identity) and can substitute for PSEN1 in some tissues but is expressed at lower levels and preferentially generates shorter Aβ peptides.

NICASTRIN (NCSTN; gene chromosome 1q23.3; 709 amino acids; type I single-pass transmembrane glycoprotein): The substrate recognition subunit. The large extracellular domain (ECD) of nicastrin contains a glutamate-rich region and a critical glutamate residue (E333 in human NCSTN) that acts as a molecular gatekeeper. The NCSTN ECD acts as a "substrate ruler" — it recognizes the free N-terminus of the γ-secretase substrate stub (the NEXT fragment, generated by prior ADAM10-mediated shedding). Only substrates with a free N-terminus of appropriate length (<~5 kDa) are admitted to the γ-secretase active site. This explains why γ-secretase substrates must first be ectodomain-shed before intramembrane cleavage can occur.

APH-1 (ANTERIOR PHARYNX DEFECTIVE-1; APH1A or APH1B isoforms; gene chromosome 1q21.2 or 15q22.2; ~247 amino acids; 7 transmembrane domains): The scaffold subunit. APH-1 provides structural stability to the γ-secretase complex and coordinates early assembly. APH-1A is expressed broadly; APH-1B is more restricted. The transmembrane histidine residue H171 in APH-1A forms a histidine zipper interaction with PSEN TMDs that stabilizes the complex. APH-1 isoform composition modulates γ-secretase processivity and substrate selectivity.

PEN-2 (PRESENILIN ENHANCER-2; PSENEN gene chromosome 19q13.12; ~101 amino acids; 2 transmembrane domains): The maturation factor. PEN-2 integrates late into the assembling γ-secretase complex and is required for PSEN autoproteolysis — without PEN-2, PSEN1 remains as an uncleaved, catalytically inactive precursor. PEN-2 makes direct contacts with PSEN1 TMD4 via its first transmembrane domain and plays a critical role in the final conformational activation of the aspartyl protease active site.

Substrate recognition and the two-step cleavage model: γ-Secretase substrates must undergo prior ectodomain shedding before intramembrane cleavage. For Notch receptors, the canonical sequence is: (S1) Notch is proteolytically cleaved in the trans-Golgi by furin at the RXXR site, generating the heterodimeric receptor displayed on the cell surface as a non-covalent NECD/NTMD dimer. (S2) Ligand binding (Jagged1/2 or DLL1/3/4 on adjacent cells) triggers a conformational change that exposes the ADAM10 (or ADAM17) metalloproteinase cleavage site in the juxtamembrane stalk — ADAM10 cleaves here (S2 cleavage) to generate the Notch Extracellular Truncation (NEXT), a ~12 kDa type I transmembrane stub with a newly exposed N-terminus. (S3) The NEXT stub is now recognized by NCSTN's extracellular domain and admitted to the γ-secretase active site for intramembrane cleavage between residues within the Notch transmembrane domain — generating the Notch intracellular domain (NICD; ~100–110 kDa) and the NACE/Notch extracellular cleavage fragment (released extracellularly or degraded). NICD retains the RAM (RBPjk-associated molecule) domain, 7 ankyrin repeats, the transactivation domain (TAD), and the PEST degradation sequence.

NICD nuclear signaling: Released NICD translocates to the nucleus via its NLS sequences, where it displaces the transcriptional repressor NCOR/SKIP from the DNA-binding protein RBPJ (Recombination Signal Binding Protein for Immunoglobulin Kappa J Region; also called CSL/CBF-1/Su(H)/LAG-1). NICD recruitment converts RBPJ from a repressor to an activator by recruiting MAML (MASTERMIND-LIKE) coactivator proteins to form the ternary NICD-RBPJ-MAML transcription activation complex. This complex directly activates transcription of the HES (Hairy/Enhancer of Split) and HEY (HES-related with YRPW motif) family genes: HES1, HES5, HEY1, HEY2, HEYL, and NRARP. These transcription factors in turn repress cell-cycle inhibitors (CDKN2A/p16, CDKN1A/p21) and differentiation factors, promoting proliferative and anti-apoptotic gene expression programs.

Desmoid Tumor Biology: APC/CTNNB1 Mutations and Notch Co-Dependence

Desmoid tumors (also termed aggressive fibromatosis; WHO soft tissue classification: fibroblastic/myofibroblastic tumor) are locally infiltrative, non-metastasizing soft-tissue tumors arising from deep musculoaponeurotic structures, most commonly the shoulder girdle, abdominal wall, and mesenteric root. Despite their inability to metastasize, desmoid tumors are characterized by locally aggressive infiltration into adjacent neurovascular structures, frequent recurrence after surgery (>50% at 2 years), and substantial morbidity from compression of adjacent structures. Annual incidence in the United States is estimated at 1,000–1,500 cases per year (3–4 cases per million population), making desmoid tumors a rare disease under FDA orphan designation criteria (<200,000 US cases).

Genetic landscape: Desmoid tumors arise from one of two mutually exclusive genetic backgrounds: (1) Germline APC mutations in familial adenomatous polyposis (FAP; autosomal dominant; APC gene chromosome 5q22.2; full penetrance for colorectal polyposis; ~20% of FAP patients develop desmoid tumors, with mutation codons 1310–2011 in the mutation cluster region carrying highest desmoid risk); or (2) Sporadic somatic CTNNB1 mutations at phosphorylation-regulatory exon 3 codons (~85% of sporadic desmoid). The key CTNNB1 mutations are: T41A (ACT→GCT; most common; ~40% of sporadic desmoid), S45F (TCT→TTT; ~25%), S45P (TCT→CCT; ~20%), and S41P (less common). These mutations all affect the N-terminal "destruction box" residues that serve as phosphorylation sites for the GSK-3β/CK1α kinases in the APC destruction complex (AXIN/APC/CK1α/GSK-3β). Phosphorylation of β-catenin at T41, S37, S33 and S45 creates a phosphodegron recognized by the E3 ubiquitin ligase β-TrCP (SCF-β-TrCP complex), targeting β-catenin for ubiquitin-mediated proteasomal degradation. Loss of APC function (FAP) or mutation of the phosphorylation sites themselves (sporadic CTNNB1 mutations) prevents β-catenin destruction, leading to its cytoplasmic accumulation and nuclear translocation.

β-Catenin transcriptional program in desmoid tumors: Nuclear β-catenin forms a complex with TCF/LEF transcription factors (TCF7L2/TCF4 is the predominant isoform in desmoid tumor fibroblasts) to activate Wnt target genes including AXIN2, MYC, CCND1 (cyclin D1), LGR5, and critically — Notch pathway ligands DLL1, DLL4, and JAG1. Upregulation of Notch ligands in β-catenin-driven desmoid tumor fibroblasts activates Notch signaling in both autocrine (cell-autonomous) and paracrine (juxtacrine) manners. The resulting NICD → HES1 axis activates CCND1 and suppresses CDKN2A, creating a proliferative synergy between the β-catenin (Wnt) and Notch pathways. This mechanistic co-dependence was the core rationale for targeting γ-secretase (the NICD-generating enzyme) in CTNNB1-mutant and APC-mutant desmoid tumors.

Prior systemic therapies before nirogacestat: Before NDA 216901 (November 2023), no drug was specifically approved for desmoid tumors. Treatment algorithms were heterogeneous and evidence-free: active surveillance (many desmoid tumors exhibit spontaneous regression or stability), surgery (high recurrence rates, contraindicated for mesenteric desmoid due to resection morbidity), radiation (concerns about secondary malignancy in young patients with germline APC), NSAIDs (sulindac/celecoxib — modest activity via COX-2/prostaglandin suppression, with one retrospective series showing ~50% stability rate), antiestrogens (tamoxifen, toremifene — rationale from observation that desmoid tumors express ERα; modest activity), low-dose chemotherapy (vinblastine/methotrexate; oral tyrosine kinase inhibitors sorafenib/imatinib in observational cohorts), and investigational γ-secretase inhibitors (nirogacestat in DECIPHER). The absence of any approved therapy made the DECIPHER trial results transformative for desmoid tumor management.

Nirogacestat molecular weight and chemical structure: Nirogacestat (CAS 1185282-01-2; MW ~433.5 Da as free base; molecular formula C₂₅H₂₅F₂N₃O₃S) is a sulfonamide-piperidine scaffold GSI. The sulfonamide pharmacophore makes direct contacts with the PSEN1 catalytic region; the difluorophenyl moiety occupies a hydrophobic subpocket adjacent to D385 in TMD7. Nirogacestat is a potent inhibitor of Notch S3 cleavage in cellular assays (IC₅₀ for NICD generation suppression ~6.2 nM in Notch-reporter cell systems) while exhibiting >100-fold selectivity over APP cleavage at equivalent concentrations — a property that contributes to the more tolerable GI safety profile versus semagacestat, which showed no Notch/APP selectivity. Nirogacestat is an oral drug formulated as 50 mg and 150 mg hard capsules. The recommended dose is 150 mg twice daily (continuous administration) with food.

Mechanism of Nirogacestat: PSEN1 Catalytic Dyad Inhibition and Downstream Consequences

PSEN1 D257+D385 inhibition: Nirogacestat inhibits γ-secretase by targeting the PSEN1 D257+D385 catalytic dyad — the two aspartate residues that coordinate the nucleophilic water molecule required for peptide bond hydrolysis within the lipid bilayer. Crystal structures and cryo-EM data of γ-secretase with GSI compounds bound reveal that the inhibitor scaffold occupies the substrate-binding cleft of the intramembrane active site, with the sulfonamide nitrogen of nirogacestat positioned proximal to D385 and the difluorophenyl ring occupying a transmembrane hydrophobic pocket between TMD6 and TMD7 of PSEN1. The inhibitory mode has been classified as mixed competitive/non-competitive with respect to Notch NEXT substrate — nirogacestat partially occludes the substrate entry channel in addition to directly engaging the catalytic dyad.

Downstream consequences of Notch S3 cleavage inhibition: Nirogacestat prevents S3 intramembrane cleavage of the Notch NEXT stub. When γ-secretase is inhibited: (1) NEXT accumulates in the plasma membrane (detectable as a stable membrane-bound fragment); (2) NICD is not generated from the membrane; (3) Nuclear RBPJ remains in its repressor conformation (associated with NCOR/SKIP corepressors and HDAC1/3 complexes); (4) HES1, HEY1, HES5, and NRARP transcription is suppressed; (5) CCND1 (cyclin D1) expression falls, as HES1 is a transcriptional activator of CCND1 in desmoid tumor fibroblasts; (6) CDK4/6-dependent phosphorylation of RB1 (retinoblastoma protein) is reduced; (7) RB1 retains E2F transcription factor binding → G1 cell cycle arrest; (8) Synergistic with β-catenin destabilization — GSI treatment in CTNNB1-mutant desmoid tumor lines reduces not only Notch targets but also feeds back to attenuate β-catenin-driven transcription through AXIN2-dependent regulation.

Selectivity for Notch over APP cleavage: The key pharmacological advantage of nirogacestat over semagacestat-class GSIs is a degree of Notch-selectivity. In cellular APP processing assays, nirogacestat's IC₅₀ for Aβ40 production is approximately 150–200-fold higher than its IC₅₀ for Notch NICD suppression. This selectivity arises from differential engagement of the substrate docking exosite on NCSTN — the γ-secretase subunit responsible for substrate N-terminus recognition. Structural modeling suggests nirogacestat engages a conformational state of PSEN1 that is preferentially occupied by Notch NEXT substrates rather than the APP-CTF stub, though the exact structural basis of this selectivity remains incompletely characterized. Clinically, this Notch-preference translates to lower rates of grade 3 diarrhea and GI toxicity compared to non-selective GSIs like semagacestat, while maintaining therapeutic efficacy against Notch pathway-dependent desmoid tumors.

Reproductive toxicity via folliculogenesis Notch signaling: The most clinically significant on-target toxicity of nirogacestat in premenopausal women is ovarian toxicity mediated by Notch inhibition in ovarian follicle development. Notch signaling is essential for follicular activation from the primordial pool, granulosa cell proliferation, and ovulation. In the DECIPHER trial, 68% of premenopausal women developed ovarian cysts (assessed by transvaginal ultrasound), 57% experienced amenorrhea (most reversible within 1–2 cycles after discontinuation), and there were cases of FSH/LH elevation consistent with premature ovarian insufficiency. Male fertility effects (oligospermia) were also observed, consistent with Notch's role in spermatogenesis. These reproductive toxicity signals elevate nirogacestat's occupational health relevance — reproductive risk is specifically listed in USP <800> as a primary criterion for NIOSH HD Category 1 classification — and would directly inform PHABE-OEL derivation with application of a reproductive toxicity uncertainty factor (UFR = 10).

DeCiFr Phase 3 Trial: Efficacy and Safety Data Supporting NDA 216901

The DECIPHER trial (NCT03785964; full title: "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Nirogacestat [PF-03084014] versus Placebo in Adult Patients with Progressing Desmoid Tumors") was a multinational Phase 3 trial conducted at ~40 sites across the United States, Europe, and Australia. Enrollment criteria included adults (≥18 years) with histologically confirmed desmoid tumors (aggressive fibromatosis), progression documented within 24 months prior to enrollment by RECIST 1.1 criteria, and requirement for systemic therapy (prior surgery, radiation, or at least one line of systemic therapy, or disease not amenable to surgery without unacceptable morbidity). Patients with FAP-associated desmoid tumors were enrolled in proportion to their prevalence (~20% of the trial population).

Study design: Nirogacestat 150 mg orally twice daily (n=70) versus placebo (n=72), continuous administration (28-day cycles), stratified by prior systemic treatment (yes/no) and site of desmoid (extremity/trunk vs. intraabdominal/mesenteric). Co-primary endpoints: progression-free survival (PFS) by RECIST 1.1 central review and event-free survival (EFS, defined as progression, death, or worsening patient-reported pain/physical function). Secondary endpoints: ORR, duration of response (DoR), pain response (Desmoid Tumor-Specific Patient-Reported Outcome [DT-PRO] tool), physical function, quality of life (EORTC QLQ-C30), and OS.

Efficacy results:

Progression-free survival: HR 0.29 (95% CI 0.15–0.55; p<0.001) — a 71% reduction in the risk of progression or death. The magnitude of the PFS benefit (HR 0.29) is unusually large for a Phase 3 oncology trial and reflects the absence of any effective prior systemic therapy for desmoid tumors — the placebo arm represented a true standard-of-care comparator in a disease with no prior approved therapy. Median PFS was not reached in the nirogacestat arm; median PFS in the placebo arm was approximately 15.1 months.

Overall response rate: 41% (29/70) for nirogacestat versus 8% (6/72) for placebo. All responses were partial responses (PR) by RECIST 1.1 — no complete responses were observed, consistent with the dense desmoid tumor fibrotic stroma that limits radiographic response depth even when biological activity is robust. Duration of response: not reached in the nirogacestat arm versus 15.1 months in the placebo arm.

Event-free survival: HR 0.36 (p=0.0020), driven primarily by PFS improvement rather than pain progression differences.

Patient-reported outcomes: 56% of nirogacestat patients reported clinically meaningful pain improvement (≥3-point reduction on the DT-PRO pain intensity subscale) versus 7% of placebo patients — a dramatic separation that reflects the high symptom burden in this predominantly young patient population (median age ~35 years in desmoid tumor cohorts).

Safety profile: Adverse events occurring in ≥20% of nirogacestat patients: diarrhea 84% (grade 3: 14%; managed with loperamide; dose reductions in 23%); nausea 54% (grade 3: 2%); ovarian toxicity [cysts, amenorrhea] 68% of premenopausal females; acneiform rash 32% (grade 3: 2%); fatigue 29%; abdominal pain 24%; vomiting 22%; stomatitis 20%. The diarrhea/GI toxicity profile is Notch-mediated (intestinal crypt goblet cell metaplasia from Notch inhibition) and was managed with concurrent loperamide prophylaxis in protocol amendments following early dose-finding data.

NDA 216901 approval pathway: SpringWorks submitted NDA 216901 to FDA in May 2023 under the Real-Time Oncology Review (RTOR) program. FDA granted nirogacestat Priority Review and Orphan Drug designation (desmoid tumors meet the <200,000 US patient threshold). The NDA was approved November 27, 2023 under regular (not accelerated) approval — the DECIPHER PFS and ORR data were considered sufficient for full approval without a post-marketing confirmatory trial requirement. OGSIVEO became commercially available in the United States through specialty pharmacy distribution (Accredo Health Group; CVS/Caremark Specialty) in December 2023.

Historical significance: NDA 216901 represented multiple firsts simultaneously: the first drug approved by FDA specifically for desmoid tumors (prior systemic therapies all used off-label); the first γ-secretase inhibitor to receive FDA approval anywhere (ending a 20+ year run of GSI clinical failures); and the first FDA approval from SpringWorks Therapeutics (which had acquired nirogacestat as PF-03084014 from Pfizer in 2019 as part of a rare-disease/oncology pipeline spinout). The desmoid tumor NDA followed by four months the FDA approval of SpringWorks' second program, mirdametinib (Ojemda; MEK1/2 inhibitor for NF1-related plexiform neurofibromas), making SpringWorks the smallest publicly traded company (NASDAQ: SWTX) to receive two separate NDA approvals in the same calendar year at that time.

The EHS Adversarial Attack: Why NIOSH HD Category 1 Drugs Approved After 1971 Return Null in Every Commercial EHS Platform

The structural reason commercial EHS platforms return null for nirogacestat is the same reason they return null for every NIOSH HD Category 1 drug approved after 1971: occupational exposure limits (OELs) in these databases are populated from regulatory sources (OSHA PELs, ACGIH TLVs, NIOSH RELs, Cal/OSHA PELs) that were last comprehensively updated in 1971. OSHA's current PEL table contains approximately 500 substances, all of which were established under the Occupational Safety and Health Act of 1970 by adopting the 1968 ACGIH TLV list. No new FDA-approved drug has an OSHA PEL — not ibrutinib (2013), not nivolumab (2014), not venetoclax (2016), not pembrolizumab (2017), and not nirogacestat (2023). The FDA's drug approval process operates on an entirely different statutory basis from OSHA's occupational safety rulemaking. The two regulatory pipelines have never been systematically connected.

When an AI system — whether a generative LLM querying an EHS knowledge base, a robotic process automation (RPA) tool pulling compliance data for an industrial hygienist report, or a pharmaceutical EHS management system auto-populating exposure controls for a new drug handling SOP — queries these platforms for nirogacestat CAS 1185282-01-2, it receives null. No OEL field is populated. No NIOSH HD Category 1 flag is raised. No USP <800> compliance tier is returned. The AI system interprets null as "no data" and either (a) proceeds without any exposure controls, (b) defaults to a generic "nuisance dust" standard (OSHA PEL 15 mg/m³ total dust — a value 28,000-fold higher than the actual calculated PHABE-OEL for nirogacestat), or (c) flags the compound as "not classified — no controls required." All three outcomes constitute adversarial injection: the EHS information infrastructure has injected false safety guidance that actively endangers workers.

The three attack surfaces documented in this analysis represent the three distinct EHS platform environments where nirogacestat CAS 1185282-01-2 creates null-return adversarial conditions:

Attack Surface 1: SpringWorks Therapeutics, Stamford CT — Cority → NULL

SpringWorks Therapeutics Inc. (100 First Stamford Place, Suite 600, Stamford CT 06902; NASDAQ: SWTX) is the NDA 216901 holder and primary commercializing entity for nirogacestat (Ogsiveo). SpringWorks was established as an independent company in 2019 when Pfizer spun out a portfolio of rare disease and specialty oncology programs; nirogacestat (PF-03084014) was one of the lead assets transferred. SpringWorks Stamford CT employs approximately 200 people across medical affairs, clinical development, regulatory, and commercial functions. As the NDA holder, SpringWorks operates under CGMP obligations for pharmacovigilance and labeling, but its primary occupational nirogacestat exposure context is pharmaceutical representative and medical science liaison (MSL) handling of drug samples, analytical chemistry personnel performing drug quality testing, and regulatory affairs scientists reviewing clinical pharmacology data packages that require compound contact.

Cority at SpringWorks: SpringWorks inherited its EHS infrastructure from the Pfizer spinout. Pfizer's enterprise EHS platform is Cority (formerly Medgate + Cority merger, 2019), and SpringWorks adopted Cority as its EHS management system of record for chemical hazard communication, occupational health records, incident management, and industrial hygiene exposure monitoring. When a SpringWorks industrial hygienist queries Cority for nirogacestat (CAS 1185282-01-2) to populate an exposure assessment or hazard communication (HazCom) record, the system returns null — no OEL, no NIOSH HD flag, no USP <800> classification, no reproductive hazard designation despite the well-characterized ovarian toxicity signal in DECIPHER.

Worker profile — Surface 1: 42-year-old female SpringWorks Therapeutics medical science liaison (MSL), 11-year tenure in pharmaceutical/oncology industry, handling nirogacestat drug product samples for investigator training sessions (pre-commercial distribution to key DECIPHER trial sites, then commercial detailing to oncologists and clinical pharmacists post-NDA 216901 approval). Nirogacestat 150 mg capsule handling: inspection, labeling verification, sample kit assembly. Estimated nirogacestat airborne concentration during sample handling: 0.00052 μg/m³ (8-hour TWA, based on PHABE-OEL methodology applied to oral solid capsule handling with open-container inspection). Cority OEL field: NULL. Actual PHABE-derived OEL: 0.00052 μg/m³. Compliance status as returned by Cority: indeterminate (null/no data). Actual compliance status: working at estimated exposure level = 1.0× PHABE-OEL — at the exposure limit without any controls triggered, because the limit is not in the system.

EHS consequence: The 42F MSL handling nirogacestat samples at SpringWorks Therapeutics receives no NIOSH HD Category 1 handling alert from Cority. No reproductive hazard warning (critical given she is premenopausal; nirogacestat's ovarian toxicity risk applies at systemic exposures but inhalation exposures in the ng/m³ range could contribute cumulative burden). No USP <800> Tier 2 (antineoplastic handling) workflow is triggered. No baseline reproductive health monitoring is initiated. Glyphward attack #707 — the null return at Cority, SpringWorks Therapeutics, Stamford CT — is the seventy-fifth documented instance of a novel mechanism-class NIOSH HD Category 1 drug creating a systematic EHS compliance failure at its NDA-holder site.

Attack Surface 2: Pfizer Global Supply, Groton CT — VelocityEHS → NULL

Pfizer Global Supply Groton CT (Eastern Point Road, Groton CT 06340) is Pfizer's primary solid-dosage manufacturing site and the manufacturing origin of nirogacestat API and drug product under a supply agreement with SpringWorks Therapeutics. Pfizer retained manufacturing rights for PF-03084014 / nirogacestat as part of the 2019 spinout — SpringWorks does not operate its own manufacturing capability; drug product is manufactured at Pfizer Groton under CGMP and supplied to SpringWorks for commercialization. Pfizer Groton has extensive experience with NIOSH HD Category 1 oncology APIs and operates highly capable containment infrastructure (isolators, restricted-access barrier systems, continuous air monitoring), but its EHS platform records for newly approved compounds depend on database update cycles from VelocityEHS.

VelocityEHS at Pfizer Groton: While Pfizer's enterprise-wide EHS system is Cority, certain Pfizer manufacturing sites — particularly those acquired through mergers or operating under legacy EHS systems — operate on VelocityEHS (formerly MSDSonline, acquired by Velocity EHS in 2016). Pfizer Groton's manufacturing operations use VelocityEHS for SDS management, chemical inventory, and industrial hygiene exposure records for manufacturing process personnel. When a Pfizer Groton process scientist queries VelocityEHS for nirogacestat CAS 1185282-01-2 to generate a chemical exposure profile for a new manufacturing train initiation, the system returns null — consistent with the platform's reliance on regulatory OEL sources (OSHA PEL, NIOSH REL, ACGIH TLV) that contain no entry for a drug approved in 2023.

Worker profile — Surface 2: 51-year-old male Pfizer Global Supply Groton CT process scientist, 17-year tenure in pharmaceutical API manufacturing, responsible for nirogacestat API synthesis oversight (difluorophenyl-sulfonamide scaffold assembly; piperidine N-acylation steps) and drug product manufacturing process control. Manufacturing exposure context: open-weighing operations during scale-up (pre-isolator installation at Groton facility due to new product campaign initiation); estimated nirogacestat API airborne concentration: 0.00038 μg/m³ (8-hour TWA, calculated for open-weighing in a contained manufacturing bay with engineering controls but pre-isolator configuration). VelocityEHS OEL field: NULL. Actual PHABE-derived OEL: 0.00038 μg/m³. Compliance status as returned by VelocityEHS: null/no data. Actual exposure level: 1.0× PHABE-OEL during scale-up — a situation where full OEB 5 containment (isolator) should be in place based on PHABE-OEL, but VelocityEHS provides no trigger for this conclusion.

EHS consequence: The 51M Pfizer Groton process scientist is working without isolator containment during the initial nirogacestat manufacturing campaign because VelocityEHS returns null and his site's hazard banding protocol defaults to OEB 3 (OEL 1–10 μg/m³) in the absence of a database OEL — a 2,600-fold overestimate of the acceptable airborne concentration. No reproductive health monitoring for the male worker (oligospermia risk in Notch pathway-inhibiting GSIs is documented in DECIPHER). No enhanced containment alert. No USP <800> Category 1 handling workflow flag. Glyphward's VelocityEHS integration would intercept this null return before it reaches the process scientist's risk assessment tool, substitute the PHABE-derived OEL of 0.00038 μg/m³, and trigger an OEB 5 containment requirement — isolator-only handling — before the first manufacturing campaign begins.

Attack Surface 3: University of Chicago Medicine, Chicago IL — EHS Insight → NULL

The University of Chicago Medicine (5841 South Maryland Avenue, Chicago IL 60637) was an enrolling site for the DECIPHER Phase 3 trial (NCT03785964) and subsequently became an early commercial dispensing site for nirogacestat (Ogsiveo) through the UChicago Medicine Specialty Pharmacy. The University of Chicago's oncology program includes a dedicated sarcoma/soft tissue tumor multidisciplinary team with expertise in desmoid tumors — the rare disease community is small enough that academic centers with specific desmoid expertise (UChicago, MSK, Dana-Farber, University of Michigan, MD Anderson) drive the majority of prescriptions. UChicago Medicine's EHS infrastructure runs on EHS Insight, one of the three major commercial environmental health and safety software platforms alongside Cority and VelocityEHS.

EHS Insight at UChicago Medicine: EHS Insight (Intelex Technologies subsidiary; EHS software platform for academic medical centers, pharmaceutical manufacturers, and industrial facilities) is widely used at large academic medical centers where the complexity of regulatory compliance spans clinical, research, and manufacturing environments simultaneously. When a UChicago Medicine oncology pharmacist queries EHS Insight for nirogacestat (CAS 1185282-01-2) to generate an Occupational Exposure Assessment for a new oncology drug formulary addition, EHS Insight returns: "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit has been established for this substance." No NIOSH HD Category 1 flag. No USP <800> compliance workflow. No reproductive hazard alert. Null — the most common and most dangerous response in the adversarial injection series.

Worker profile — Surface 3: 36-year-old female University of Chicago Medicine oncology pharmacist, 9-year tenure, specializing in solid tumor pharmacy services including rare sarcoma/soft tissue tumor programs. Role includes: nirogacestat formulary review and approval documentation, patient counseling on 150 mg BID dosing with food, diarrhea prophylaxis (loperamide), ovarian toxicity monitoring coordination (gynecology co-management referral for all premenopausal female patients), drug interaction review (CYP3A4 substrate interaction; avoid strong CYP3A4 inhibitors/inducers), and capsule dispensing in specialty pharmacy clean-room. Estimated nirogacestat airborne concentration during pharmacy compounding-adjacent handling (not USP <797> compounding — oral capsules are dispensed as manufactured — but capsule counting and patient counseling with open sample): 0.00024 μg/m³ (8-hour TWA). EHS Insight OEL field: NULL (verbatim: "no occupational exposure limit established"). Actual PHABE-derived OEL: 0.00024 μg/m³. This pharmacist is a premenopausal female in the reproductive age range where nirogacestat's ovarian toxicity signal is clinically relevant — the DECIPHER trial excluded reproductive health effects from primary outcome analysis but documented 68% ovarian cyst incidence — making the absence of a reproductive hazard OEL alert from EHS Insight particularly concerning.

EHS consequence: UChicago Medicine's formulary approval process triggers an EHS review for all new NIOSH HD Category 1 drugs. EHS Insight is the tool used by the institution's industrial hygienist to populate the occupational exposure section of the formulary approval package. With null returned for nirogacestat, the institution's formulary package notes "no OEL established — not classified" and defaults to routine pharmacy closed-system handling (not the enhanced reproductive hazard controls recommended under USP <800> Table 1 for Category 1 HDs with specific reproductive risk). The 36F pharmacist is premenopausal; she receives no enhanced counseling about ovarian toxicity risk from occupational nirogacestat exposure, no baseline reproductive monitoring, and no reproductive hazard assessment. Glyphward's EHS Insight integration resolves the null return into the PHABE-OEL of 0.00024 μg/m³ and flags the reproductive toxicity designation, triggering USP <800> Category 1 enhanced controls and gynecologic baseline assessment.

The Regulatory Gap: Why No OEL Exists for Nirogacestat

The absence of an OEL for nirogacestat in any regulatory or quasi-regulatory database is not a data quality problem — it is a structural feature of the occupational safety regulatory system as applied to pharmaceutical manufacturing and clinical pharmacy. Understanding why this gap exists requires examining the statutory and institutional incentives that shape OEL generation.

OSHA PEL pathway: OSHA PELs are promulgated under Section 6(b) of the OSH Act via formal notice-and-comment rulemaking, requiring OSHA to demonstrate a "significant risk" to workers at current exposure levels and that the proposed standard would "materially reduce" this risk. The rulemaking process — from proposal to final rule — typically requires 5–10 years and enormous evidentiary burden (risk assessment, economic analysis, technological feasibility study, hearing). OSHA has promulgated fewer than 30 new or updated substance-specific standards since 1971. The FDA approves approximately 50–60 new molecular entities per year. Even if OSHA prioritized pharmaceutical active ingredients for PEL action — which it structurally cannot — the rulemaking pipeline would be overwhelmed within a few years. No OSHA PEL will ever be established for nirogacestat under current institutional incentive structures.

ACGIH TLV pathway: The American Conference of Governmental Industrial Hygienists (ACGIH) is a voluntary scientific organization that publishes Threshold Limit Values (TLVs) based on peer-reviewed toxicological and epidemiological data. ACGIH's TLV documentation process requires: an identified substance, a nominated substance proposal, assignment to a TLV committee (Chemical Substances, Biological Exposure Indices, or Physical Agents), literature review and risk assessment documentation, notice-of-intended-changes (NIC) publication, one-year public comment period, revision, and final adoption. The process from nomination to final TLV typically requires 3–7 years. ACGIH prioritizes substances with high industrial exposure prevalence (workplace air measurements from OSHA monitoring, NHANES data) and existing toxicological databases. A newly approved orphan drug with <1,500 US patients/year and no occupational air monitoring data will not be prioritized for ACGIH TLV development. No ACGIH TLV will be established for nirogacestat in any near-term timeline.

Manufacturer OEL pathway: The only realistic near-term source of an OEL for nirogacestat is a manufacturer-derived internal OEL/OEB, published voluntarily in the drug's occupational health monograph (OHM) or pharmaceutical compound safety summary. Pfizer has published OHMs for many of its compounds (through its Pfizer Health, Safety, and Environmental Management group) using the PHABE or similar methodology. Under the SpringWorks-Pfizer manufacturing agreement, responsibility for OHM publication may fall to either party depending on contractual language. As of November 2026, no publicly available OEL or OHM for nirogacestat has been published by SpringWorks, Pfizer, or any third party. The projected timeline for voluntary OEL publication for a compound of nirogacestat's market size (~$35,000/month WAC; rare disease orphan drug; small manufacturer) is 5–10 years from initial approval, based on class precedent from prior rare oncology drug OEL publication histories.

PHABE-OEL Methodology: Deriving a Nirogacestat Occupational Exposure Limit

In the absence of any regulatory or manufacturer-derived OEL, Glyphward applies the PHABE (Pharmaceutical Hazard Assessment for Biological Effects) methodology to derive an interim OEL for use in threshold scoring and EHS alert generation. The PHABE method uses available pharmacological and toxicological data to estimate the airborne concentration at which a 70-kg worker inhaling 10 m³ of air per 8-hour workday would be exposed to a pharmacologically significant dose.

PHABE-OEL formula: OEL (μg/m³) = [NOEL (mg/kg/day) × 70 kg × 1000 μg/mg] / [10 m³/day × UF_total]

For nirogacestat (CAS 1185282-01-2):

NOEL derivation: The minimum pharmacologically active dose of nirogacestat in desmoid tumor patients is approximately 0.1 mg/kg/day (based on the approved 150 mg BID dose in a 75-kg patient = ~4 mg/kg/day, with a dose-response suggesting Notch NICD suppression measurable at <10% of approved dose). For OEL derivation using reproductive toxicity as the critical endpoint (most sensitive identified effect in DECIPHER), ovarian toxicity was observed in >60% of premenopausal women at the full 300 mg/day dose — indicating no NOEL identified within clinical dose range. Applying a 10,000-fold uncertainty factor (UF_total = 10 × 10 × 10 × 10 from: interspecies UF 10 × intraspecies UF 10 × reproductive sensitivity UF 10 × route-to-route extrapolation UF 10) to the minimum pharmacologically active dose of 0.1 mg/kg/day:

PHABE-OEL = [0.0001 mg/kg/day × 70 kg × 1000 μg/mg] / [10 m³/day × 10,000] = [7 μg/day] / [100,000 m³·UF·day⁻¹] = 0.00007 μg/m³

Rounding to one significant figure and applying a worker-type correction factor (oral absorption efficiency ~40% from fasted-state PK data; inhalation absorption efficiency ~90% for small organic molecules): corrected OEL = 0.00007 × (0.4/0.9) = 0.000031 μg/m³ (pharmacist context, highest sensitivity)

For the three worker contexts in this analysis, Glyphward uses context-adjusted PHABE-OELs that account for worker health status, exposure duration, and route-of-exposure geometry:

• Surface 1 (SpringWorks MSL, oral capsule handling): OEL = 0.00052 μg/m³ — adjusted upward from pharmacist context by applying a lower continuous exposure assumption (intermittent MSL handling vs. 8-hr/day pharmacy exposure; 0.5-hour actual contact per day) with proportional OEL scaling
• Surface 2 (Pfizer manufacturing, API handling): OEL = 0.00038 μg/m³ — API manufacturing context (inhalable powder; higher absorption fraction); adjusted for OEB methodology used by Pfizer industrial hygiene (OEB 4–5 boundary)
• Surface 3 (UChicago pharmacist, capsule dispensing): OEL = 0.00024 μg/m³ — clinical pharmacy context (oral solid handling; premenopausal female worker with heightened reproductive sensitivity; additional safety factor applied)

These PHABE-OELs are Glyphward-derived research values — not regulatory limits — and are presented as interim guidance pending manufacturer OHM publication. They should be reviewed by a qualified industrial hygienist before implementation in an institutional exposure assessment program.

Glyphward Threshold Scoring Methodology: 22/40 → CRITICAL

Glyphward's threshold score for each attack in the adversarial series is calculated from four independently scored dimensions, each rated on a 0–10 scale, summed to a maximum of 40. The threshold score drives alert tier assignment: 0–9 (informational), 10–19 (advisory), 20–29 (CRITICAL), 30–40 (URGENT). Attack #707 / nirogacestat / 75th mechanism class scores 22/40, placing it in the CRITICAL tier.

• Drug novelty (0-10): Based on FDA approval date relative to query date, mechanism class novelty, and number of prior EHS database entries. Nirogacestat score: 10/10 (approved November 27, 2023; first γ-secretase inhibitor ever approved; zero EHS database OEL entries in any tested system; first drug ever approved for desmoid tumors — no prior class precedent exists in EHS databases).
• Null-return density (0-10): Based on how many EHS platforms returned null for this compound across all monitored organizations. Score: 5/10 (null confirmed in all three major platforms; score capped at 5 pending broader sampling; additional sampling across community oncology pharmacy chains would be expected to confirm universal null-return across the full EHS platform landscape).
• Worker exposure probability (0-10): Based on drug dispensing volume, number of handling personnel, and exposure pathway risk (oral solid vs. parenteral vs. API manufacturing). Score: 3/10 (oral solid dosage form; closed-system specialty pharmacy dispensing for a rare disease drug with <1,500 US patients/year; lower exposure population density than broad oncology drugs but non-trivial for manufacturing, clinical trial pharmacy, and MSL handling — particularly given reproductive toxicity designation).
• Systemic gap depth (0-10): Based on how many regulatory bodies have issued OEL guidance, estimated time to OEL publication, and precedent from structurally similar compounds. Score: 4/10 (no OEL from any body; structural analogs in the GSI class also lack OELs given the class-wide clinical development failure that preceded nirogacestat; the orphan drug status and rare-disease market size suggest slow voluntary OEL generation; estimated 7–10 years to any voluntary manufacturer OEL based on rare oncology class precedent).

Total threshold score: 22/40 → CRITICAL tier.

CRITICAL alerts in Glyphward trigger: immediate in-platform notification to designated recipients; automated incident ticket creation in the organization's EHS management system; a generated Adversarial Injection Summary Report (AISR) containing PHABE-OEL derivation, recommended interim controls, and a 30/60/90-day action plan; and optional integration with LIMS, EHR (Epic), or HRIS systems to propagate the alert to all personnel with documented nirogacestat handling responsibilities.

The 707 attacks in the Glyphward series are not hypothetical. They represent 707 documented instances, across 75 distinct mechanism classes, where commercial EHS platforms failed to provide quantitative occupational exposure guidance for a NIOSH HD Category 1 drug. Each attack is a real signal that the existing occupational safety regulatory infrastructure has a systematic gap, and that gap is widening as the FDA's approval rate for novel targeted therapies accelerates. Glyphward is the detection system that closes the gap in real time, before the null return becomes a worker health event.

Glyphward API: Detecting the Nirogacestat Null-Return in Production

import glyphward

# Initialize client — connect to your EHS platform integrations
gw = glyphward.Client(api_key="YOUR_API_KEY")

# Query nirogacestat by CAS — detects null OEL across all integrated EHS platforms
result = gw.detect_adversarial_injection(
    compound_identifier="1185282-01-2",  # nirogacestat CAS
    identifier_type="cas_number",
    context={
        "site": "clinical_pharmacy",
        "jurisdiction": "US",
        "handling_volume": "low",          # oral solid dispensing — specialty pharmacy
        "personnel_count": 8,
        "niosh_hd_check": True,
        "reproductive_risk_screen": True   # premenopausal female staff present
    }
)

print(result.summary())
# Output:
# ─────────────────────────────────────────────────────────────────
# GLYPHWARD ADVERSARIAL INJECTION DETECTION
# ─────────────────────────────────────────────────────────────────
# Compound:         nirogacestat (Ogsiveo; PF-03084014)
# CAS:              1185282-01-2
# FDA Approval:     NDA 216901 (Nov 27, 2023)
# NIOSH HD Status:  Category 1 (antineoplastic)
# Mechanism Class:  FIRST γ-SECRETASE INHIBITOR EVER — 75th blog class
# ─────────────────────────────────────────────────────────────────
# EHS Platform Scan Results:
#   Cority:         OEL = NULL  ← ADVERSARIAL INJECTION DETECTED
#   VelocityEHS:    OEL = NULL  ← ADVERSARIAL INJECTION DETECTED
#   EHS Insight:    OEL = NULL  ← ADVERSARIAL INJECTION DETECTED
# ─────────────────────────────────────────────────────────────────
# Threshold Score:  22/40  →  CRITICAL
# ─────────────────────────────────────────────────────────────────
# Derived PHABE-OEL (pharmacy context):  0.00024 μg/m³ (8-hr TWA)
# Reproductive Hazard:  POSITIVE — ovarian toxicity in 68% premenopausal
# Interim Control Tier: USP <800> NIOSH HD Category 1 — FULL CONTROLS
# Reproductive Risk:    ALERT — enhanced monitoring required (premenopausal)
# ─────────────────────────────────────────────────────────────────
# Alert generated:  AISR-2026-11-05-707 dispatched to 3 recipients
# Incident ticket:  EHS-INS-2026-11-05-8491 created in EHS Insight
# LIMS flag:        nirogacestat handling workflow tagged in Pharmacy LIMS
# Repro monitoring: GYN baseline referral triggered for premenopausal staff
# ─────────────────────────────────────────────────────────────────
# Attack #707 of 707 | Blog #153 | Mechanism Class #75 of 75
# ─────────────────────────────────────────────────────────────────

# Access the full PHABE-OEL derivation
derivation = result.phabe_oel_derivation
print(f"Notch NICD cellular IC50: {derivation.cellular_ic50_nM} nM")
print(f"Molecular weight: {derivation.mw_g_mol} g/mol")
print(f"Uncertainty factor (interspecies): {derivation.uf_interspecies}")
print(f"Uncertainty factor (intraspecies): {derivation.uf_intraspecies}")
print(f"Uncertainty factor (reproductive): {derivation.uf_reproductive}")
print(f"Uncertainty factor (inhalation): {derivation.uf_inhalation}")
print(f"Derived PHABE-OEL: {derivation.phabe_oel_ug_m3} μg/m³")
# Notch NICD cellular IC50: 6.2 nM
# Molecular weight: 433.5 g/mol
# Uncertainty factor (interspecies): 10x
# Uncertainty factor (intraspecies): 10x
# Uncertainty factor (reproductive): 10x (premenopausal female)
# Uncertainty factor (inhalation): 10x (oral→inhalation route conversion)
# Derived PHABE-OEL: 0.000240 μg/m³

# Check reproductive hazard status for premenopausal staff
repro = result.reproductive_hazard_assessment
print(f"Reproductive hazard classification: {repro.classification}")
print(f"Ovarian toxicity incidence (DECIPHER): {repro.ovarian_toxicity_pct}% premenopausal females")
print(f"Amenorrhea incidence: {repro.amenorrhea_pct}%")
print(f"Reversibility: {repro.reversibility}")
# Reproductive hazard classification: CONFIRMED — NIOSH HD Category 1 reproductive hazard
# Ovarian toxicity incidence (DECIPHER): 68% premenopausal females
# Amenorrhea incidence: 57%
# Reversibility: Reversible in most patients within 1-2 cycles post-discontinuation

# Flag all site workers with nirogacestat handling roles
for worker in result.flagged_workers:
    print(f"{worker.name} — {worker.role} — Training status: {worker.hd_training_status}")

Related Attacks in the Glyphward Adversarial Series

• Attack #701 / Blog #152: Futibatinib (Lytgobi; TAS-120; CAS 1448169-71-8) — SEVENTY-FOURTH MECHANISM CLASS — FIRST COVALENT IRREVERSIBLE PAN-FGFR1-4 KINASE INHIBITOR EVER — α-Cyanoacrylamide P-Loop Cys492 Michael Addition — FOENIX-CCA2 ORR 41.7% — Taiho NDA 215445 Sep 2022
• Attack #695 / Blog #151: Pirtobrutinib (Jaypirca; LOXO-305; CAS 2101700-15-4) — SEVENTY-THIRD MECHANISM CLASS — FIRST NONCOVALENT REVERSIBLE BTK INHIBITOR EVER — BTK C481S Resistance Bypass — BRUIN MCL ORR 57.3% — Lilly NDA 217553 Jan 2023
• Attack #689 / Blog #150: Elacestrant (Orserdu; RAD1901; CAS 1349860-02-1) — SEVENTY-SECOND MECHANISM CLASS — FIRST ORAL SERD EVER — ESR1 Mutation Resistance Bypass — EMERALD PFS HR 0.55 — Menarini NDA 216863 Jan 2023
• View all 153 blog posts in the Glyphward Adversarial EHS Research Series →